The other trial is a Phase II study evaluating the safety and efficacy of allogeneic pancreatic tumor cells genetically modified to express the GM-CSF factor with chemoradiotherapy for resected stage I or stage II adenocarcinoma of the pancreas (NCT00084383). Here, CSF2 is linked to pancreatic neoplasm.